Pasithea Therapeutics Files 8-K on Other Events
Ticker: KTTAW · Form: 8-K · Filed: Dec 15, 2025 · CIK: 1841330
Sentiment: neutral
Topics: 8-K, corporate-event
TL;DR
Pasithea Therapeutics filed an 8-K for 'Other Events' on 12/15/25.
AI Summary
Pasithea Therapeutics Corp. filed an 8-K on December 15, 2025, reporting an event on December 12, 2025. The filing pertains to "Other Events" and includes details about common stock and warrants. The company is incorporated in Delaware and its principal executive offices are located in Miami Beach, FL.
Why It Matters
This 8-K filing indicates a corporate event or update for Pasithea Therapeutics Corp., requiring disclosure to investors.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for 'Other Events' and does not immediately indicate significant financial or operational risk.
Key Players & Entities
- Pasithea Therapeutics Corp. (company) — Registrant
- December 12, 2025 (date) — Earliest event date
- December 15, 2025 (date) — Filing date
- Miami Beach, FL (location) — Principal executive offices
FAQ
What specific 'Other Event' is being reported by Pasithea Therapeutics Corp. in this 8-K filing?
The provided text does not specify the exact 'Other Event'; it only categorizes the filing under 'Other Events'.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on December 12, 2025.
What is the principal executive office address for Pasithea Therapeutics Corp.?
The principal executive offices are located at 1111 Lincoln Road, Suite 500, Miami Beach, FL 33139.
What is the company's fiscal year end?
The company's fiscal year end is December 31.
What is the SIC code for Pasithea Therapeutics Corp.?
The Standard Industrial Classification (SIC) code is 2834 for Pharmaceutical Preparations.
Filing Stats: 495 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2025-12-15 08:00:41
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share KTTA The Nasdaq Capital M
- $1.00 m — Company was not in compliance with the $1.00 minimum bid price requirement, as set for
- $1.00 — ntained a closing bid price at or above $1.00 per share for a sufficient number of co
Filing Documents
- ea0269602-8k_pasithea.htm (8-K) — 27KB
- 0001213900-25-121466.txt ( ) — 233KB
- ktta-20251212.xsd (EX-101.SCH) — 4KB
- ktta-20251212_def.xml (EX-101.DEF) — 26KB
- ktta-20251212_lab.xml (EX-101.LAB) — 36KB
- ktta-20251212_pre.xml (EX-101.PRE) — 25KB
- ea0269602-8k_pasithea_htm.xml (XML) — 6KB
01. Other Events
Item 8.01. Other Events. As previously reported, on June 23, 2025, Pasithea Therapeutics Corp. (the "Company") received a notice from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") indicating that the Company was not in compliance with the $1.00 minimum bid price requirement, as set forth in Nasdaq Listing Rule 5550(a)(2), and had 180 days in which to regain compliance, or until December 22, 2025. On December 12, 2025, the Company received a letter from Nasdaq stating that its common stock had maintained a closing bid price at or above $1.00 per share for a sufficient number of consecutive business days to regain compliance with the minimum bid price requirement, and that the matter is now closed. 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PASITHEA THERAPEUTICS CORP. By: / s / Tiago Reis Marques Name: Dr. Tiago Reis Marques Title: Chief Executive Officer Date: December 15, 2025 2